Fatty acid study aims to unlock secrets of rare metabolic disease
NCT ID NCT06623032
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study looks at how medium-chain and long-chain fatty acids affect metabolism in people with Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) and healthy individuals. Researchers will measure ketone bodies, resting metabolic rate, and other factors after participants consume these fats. The goal is to better understand the body's response in MCADD, which could lead to improved dietary advice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Medium-Chain Fatty Acid (MCFA) and Long-Chain Fatty Acid (LCFA)
- What this could lead to
- If successful, this study could provide insights into how different fats affect people with MCADD, potentially guiding dietary recommendations to manage the condition better.
- What could go wrong
- This is a small, early-stage study with only 30 participants, so results may not apply broadly. It focuses on short-term metabolic effects, not long-term outcomes or treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Copenhagen
RECRUITINGCopenhagen, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Could a liver drug help kids and adults with rare metabolic disorder?
- Small study tests exercise safety in kids with MCADD
- Could a fatty acid drug stop dangerous sugar crashes in rare disease?
- Could a fatty acid drug stop dangerous sugar crashes in rare disease?
- Could a urea cycle drug help MCAD patients fast longer?